Ablynx NV (ABLX.BR) Key Developments | Reuters.com
Edition:
United States

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

11.27EUR
11:36am EDT
Change (% chg)

€0.46 (+4.21%)
Prev Close
€10.81
Open
€11.41
Day's High
€11.48
Day's Low
€11.11
Volume
262,836
Avg. Vol
171,551
52-wk High
€16.20
52-wk Low
€10.00

Latest Key Developments (Source: Significant Developments)

Ablynx announces nanobody drug discovery collaboration with Novo Nordisk
Wednesday, 25 Nov 2015 01:00am EST 

Ablynx NV:Announces nanobody drug discovery collaboration with Novo Nordisk A/S.Ablynx to receive a 5 million euro upfront payment, research funding, potential future milestones and royalties on net sale.If Novo Nordisk decides to exercise option to second programme, company will pay ablynx an exercise fee of 4 million euros.Collaboration and licensing agreement with Novo Nordisk to discover and develop novel multi-specific Nanobody drug candidates.In addition, Ablynx is eligible to receive potential development, regulatory and commercial milestone payments of up to 182 million euros per programme.Novo Nordisk will be responsible for the development, manufacturing and commercialisation of any products resulting from this agreement.  Full Article

Ablynx gives FY 2015 cash burn guidance
Wednesday, 18 Nov 2015 01:00am EST 

Ablynx NV:Company expects its net cash burn for the full year 2015 to be at the lower end of the previously guided range of 70-80 million euros.  Full Article

Ablynx partner Boehringer Ingelheim presented positive in vivo proof-of-mechanism data with bi-specific nanobody
Thursday, 5 Nov 2015 01:00am EST 

Ablynx NV:Ablynx's partner Boehringer Ingelheim presented positive in vivo proof-of-mechanism data with bi-specific nanobody at euro global summit on cancer therapy.  Full Article

Ablynx initiates a multinational phase III study with Caplacizumab in patients with acquired TTP
Tuesday, 29 Sep 2015 01:00am EDT 

Ablynx NV:Initiates a multinational phase III study with Caplacizumab in patients with acquired TTP, a rare blood clotting disorder.Is on track to file for conditional approval of Caplacizumab in Europe in 2017 for treatment of acquired TTP.  Full Article

Ablynx initiates phase II SLE study with its anti-IL-6R Nanobody
Tuesday, 4 Aug 2015 01:00am EDT 

Ablynx NV:Ablynx initiates phase II SLE study with its anti-IL-6R Nanobody, partnered with Abbvie Inc .Study's primary endpoint is the percentage of subjects who achieved a response at week 24 according to the composite BICLA score (BILAG-based Combined Lupus Assessment).  Full Article

Ablynx expands its immuno-oncology collaboration with Merck & Co
Wednesday, 22 Jul 2015 01:00am EDT 

Ablynx NV:Significantly expands its immuno-oncology collaboration with Merck & Co Inc.Expanded deal includes new targets and target combinations directed against immune checkpoint modulators.Expanding size and scope of deal to include up to 12 additional Nanobody programmes.Under terms of this four year expansion, Ablynx will receive a 13 million euro upfront payment.Ablynx will be eligible to receive additional exclusivity fees, depending on the number of programmes for which Merck decides to exercise its licensing option, plus development, regulatory and commercial milestone payments of up to 340 million euros per programme.Also eligible to tiered royalties on annual net sales upon commercialisation of any Nanobody products.  Full Article

Ablynx NV and Taisho Pharmaceutical Co Ltd sign exclusive license agreement for development and commercialisation of anti-TNF nanobody (ozoralizumab) in Japan
Tuesday, 30 Jun 2015 02:08am EDT 

Ablynx NV:Says that it has entered into exclusive license agreement with Taisho Pharmaceutical Co Ltd for development and commercialisation of Ablynx's anti-TNFa Nanobody, ozoralizumab, in Japan, for treatment of RA.Says that under terms of agreement, Taisho will be responsible for development, registration and commercialisation of anti-TNFa Nanobody therapeutics in Japan.Says Ablynx will receive an upfront payment of $3 million and is entitled to receive development and commercial milestone payments plus royalties based on annual net sales of anti-TNFa Nanobody therapeutics generated in Japan.  Full Article

Ablynx announces presentations on Caplacizumab
Wednesday, 17 Jun 2015 01:01am EDT 

Ablynx NV:Ablynx announces presentations on its potential treatment for acquired TTP, Caplacizumab, at the 2015 annual meeting of the ISTH.Presentation is of additional data from the post-hoc analysis of the worldwide Phase II TITAN study with its wholly-owned anti-von Willebrand Factor (vWF) Nanobody Caplacizumab.Primary endpoint of a reduction in time to platelet normalization was achieved.  Full Article

Ablynx says 100 million euros private placement was successful
Wednesday, 20 May 2015 09:58am EDT 

Ablynx NV:Says 100 million euros private placement in convertible bonds was successful.  Full Article

Ablynx launches private placement of 100 mln euro convertible bond
Wednesday, 20 May 2015 03:10am EDT 

Ablynx NV:Launches private placement of up to 100 million euros ($110.83 million) in convertible bonds with due date in May 2020.Most of net proceeds from offering will be used to accelerate development of clinical product portfolio, start pre-commercial activities and to begin clinical development of early stage product candidates.  Full Article

BRIEF-Vectura says Ablynx to exercise a license option on Fox device

* Ablynx to exercise option to license Vectura's Fox device for use in its forthcoming phase IIB efficacy study of its inhaled anti-rsv nanobody Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 806 749 1136)